What's in Children's Cancer Group, China's pipeline?

Children's Cancer Group, China has 15 drugs in our index: 0 marketed, 0 filed, 8 in Phase 3, 7 in Phase 2, 0 in Phase 1.

Which companies overlap with Children's Cancer Group, China's portfolio?

Top competitors by shared drug class: Polish Adult Leukemia Group, Sun Yat-sen University, Zhejiang Cancer Hospital, Asan Medical Center, The First Affiliated Hospital with Nanjing Medical University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/children-s-cancer-group-china.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Children's Cancer Group, China — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Children's Cancer Group, China pipeline: 0 marketed, 0 filed, 8 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 8 Phase 3 7 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Course B3 +Vin	Course B3 +Vin	phase 3	Multi-agent chemotherapy combination		Oncology
Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase	Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase	phase 3	Combination chemotherapy regimen		Oncology
Course B2 +Vin	Course B2 +Vin	phase 3	Chemotherapy combination regimen		Oncology
Course A1 + Vin	Course A1 + Vin	phase 3	Multi-agent chemotherapy combination		Oncology
Course A2 + Vin	Course A2 + Vin	phase 3	Combination chemotherapy		Oncology
Course A3 + Vin	Course A3 + Vin	phase 3	Multi-agent chemotherapy combination		Oncology
Methotrexate, 6-mercaptopurine	Methotrexate, 6-mercaptopurine	phase 3	Antimetabolite combination	Dihydrofolate reductase (methotrexate); hypoxanthine-guanine phosphoribosyltransferase (6-mercaptopurine)	Oncology
Course B1 +Vin	Course B1 +Vin	phase 3	Multi-agent chemotherapy regimen		Oncology

Therapeutic area mix

Oncology · 11
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Polish Adult Leukemia Group · 3 shared drug classes
Sun Yat-sen University · 3 shared drug classes
Zhejiang Cancer Hospital · 2 shared drug classes
Asan Medical Center · 2 shared drug classes
The First Affiliated Hospital with Nanjing Medical University · 2 shared drug classes
University Hospital, Bordeaux · 2 shared drug classes
PETHEMA Foundation · 2 shared drug classes
Amgen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Children's Cancer Group, China:

Cite this brief

Drug Landscape (2026). Children's Cancer Group, China — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/children-s-cancer-group-china. Accessed 2026-05-17.